Review on Approved and Inprogress COVID-19 Vaccines
Iranian Journal of Pharmaceutical Research · 24.01.2022 · 21 (1)
DOI: 10.5812/ijpr.124228 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 24.01.2022. Verfasst von Amir Farnudian-Habibi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Biomaterials, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
: The last generation of Coronavirus named COVID-19 is responsible for the recent worldwide outbreak. Concerning the widespread and quick predominance, there is a critical requirement for designing appropriate vaccines to surmount this grave problem. Correspondingly, in this revision, COVID-19 vaccines (which are being developed until March 29th, 2021) are classified into specific and non-specific categories. Specific vaccines comprise genetic-based vaccines (mRNA, DNA), vector-based, protein/recombinant protein vaccines, inactivated viruses, live-attenuated vaccines, and novel strategies including microneedle arrays (MNAs), and nanoparticles vaccines. Moreover, specific vaccines such as BCG, MRR, and a few other vaccines are considered Non-specific. What is more, according to the significance of Bioinformatic sciences in the cutting-edge vaccine design and rapid outbreak of COVID-19, herein, Bioinformatic principles including reverse vaccinology, epitopes prediction/selection and, their further applications in the design of vaccines are discussed. Last but not least, safety, challenges, advantages, and future prospects of COVID-19 vaccines are highlighted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Biomaterials, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- Medical Biomaterials Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Clinical Pharmacy, Virtual University of Medical Sciences, Tehran, Iran.
- Department of Medical Education, Virtual University of Medical Sciences, Tehran, Iran.
- Australasian Nanoscience and Nanotechnology Initiative (ANNI), 8054 Monash University LPO, Clayton, 3168, Victoria, Australia.
- School of Electrical and Computer Engineering, College of Engineering, University of Tehran, 14395-515 Tehran, Iran.
ORCID-Profile: Amir Farnudian-Habibi, Seyed Nasser Ostad, Mazda Rad-Malekshahi
Zitieren
APA
Farnudian-Habibi, A., Mirjani, M., Montazer, V., Aliebrahimi, S., Katouzian, I., Abdolhosseini, S., Rahmani, A., Keyvani, H., Ostad, S. N., & Rad-Malekshahi, M. (2022). Review on Approved and Inprogress COVID-19 Vaccines. Iranian Journal of Pharmaceutical Research, 21(1). https://doi.org/10.5812/ijpr.124228
Vancouver
Farnudian-Habibi A, Mirjani M, Montazer V, Aliebrahimi S, Katouzian I, Abdolhosseini S, et al. Review on Approved and Inprogress COVID-19 Vaccines. Iranian Journal of Pharmaceutical Research. 2022;21(1). doi:10.5812/ijpr.124228
BibTeX
@article{FarnudianHabibi2022,
author = {Farnudian-Habibi, Amir and Mirjani, Mobina and Montazer, Vahideh and Aliebrahimi, Shima and Katouzian, Iman and Abdolhosseini, Saeed and Rahmani, Ali and Keyvani, Hossein and Ostad, Seyed Nasser and Rad-Malekshahi, Mazda},
title = {Review on Approved and Inprogress COVID-19 Vaccines},
journal = {Iranian Journal of Pharmaceutical Research},
year = {2022},
volume = {21},
number = {1},
doi = {10.5812/ijpr.124228}
}
EUVIMED